UY39393A - Formulaciones de un inhibidor de mcl-1 - Google Patents

Formulaciones de un inhibidor de mcl-1

Info

Publication number
UY39393A
UY39393A UY0001039393A UY39393A UY39393A UY 39393 A UY39393 A UY 39393A UY 0001039393 A UY0001039393 A UY 0001039393A UY 39393 A UY39393 A UY 39393A UY 39393 A UY39393 A UY 39393A
Authority
UY
Uruguay
Prior art keywords
formulations
mcl
inhibitor
amg
solid
Prior art date
Application number
UY0001039393A
Other languages
English (en)
Inventor
Markian Stec
James E Huckle
Wu Tian
Darren L Reid
Fernando Alvarez-Nunez
Brown Sean
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of UY39393A publication Critical patent/UY39393A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)

Abstract

En la presente se proporcionan dispersiones sólidas que comprenden AMG 397, métodos para preparar la dispersión sólida y formulaciones farmacéuticas que comprenden AMG 397.
UY0001039393A 2020-08-26 2021-08-23 Formulaciones de un inhibidor de mcl-1 UY39393A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063070630P 2020-08-26 2020-08-26

Publications (1)

Publication Number Publication Date
UY39393A true UY39393A (es) 2022-02-25

Family

ID=77802255

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039393A UY39393A (es) 2020-08-26 2021-08-23 Formulaciones de un inhibidor de mcl-1

Country Status (11)

Country Link
US (1) US20230312606A1 (es)
EP (1) EP4203922A1 (es)
JP (2) JP2022039996A (es)
CN (1) CN116113473A (es)
AR (1) AR123327A1 (es)
AU (1) AU2021330948A1 (es)
CA (1) CA3192624A1 (es)
MX (1) MX2023002352A (es)
TW (1) TW202222321A (es)
UY (1) UY39393A (es)
WO (1) WO2022046690A1 (es)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6453507B2 (ja) * 2017-03-30 2019-01-16 アムジエン・インコーポレーテツド Ｍｃｌ−１タンパク質を阻害する化合物

Also Published As

Publication number Publication date
AR123327A1 (es) 2022-11-23
EP4203922A1 (en) 2023-07-05
JP2023539198A (ja) 2023-09-13
JP2022039996A (ja) 2022-03-10
AU2021330948A1 (en) 2023-03-30
CN116113473A (zh) 2023-05-12
MX2023002352A (es) 2023-04-14
TW202222321A (zh) 2022-06-16
CA3192624A1 (en) 2022-03-03
US20230312606A1 (en) 2023-10-05
WO2022046690A1 (en) 2022-03-03

Similar Documents

Publication Publication Date Title
CL2020002405A1 (es) Inhibidores de kras g12c y métodos para su uso (divisional de la solicitud no. 201903394)
AR113031A1 (es) Composiciones de nanopartículas lipídicas (lnp) que comprende arn
CL2021003191A1 (es) Inhibidores de tead y usos de los mismos
CL2021003190A1 (es) Inhibidores de tead y usos de los mismos
DOP2019000180A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
UY38403A (es) Moduladores de la alfa-1 antitripsina
CO2020006227A2 (es) Moduladores de la vía de estrés integrada
MX2020004537A (es) Moduladores de la vía integrada del estrés.
CO2021006098A2 (es) Moduladores de profármacos de la vía de estrés integrada
CO2020012060A2 (es) Inhibidores de la arginasa
CL2021001075A1 (es) Agonista del receptor de glucocorticoides e inmunoconjugados de este solicitud divisional de 202001452)
AR107529A1 (es) Compuestos, composiciones y métodos para la estratificación de pacientes de cáncer y su tratamiento
CL2019001993A1 (es) Inhibidores selectivos de jak1.
CL2020002101A1 (es) Formulaciones de liberación sostenida de ácido bempedoico.
CL2020002624A1 (es) Formulaciones de inmunoconjugado anti-cd79b estables.
CO2021010786A2 (es) Toxinas apxia, apxiia y apxiiia inactivadas
CL2022002402A1 (es) Inhibidores del eif4e y sus usos
CL2017000563A1 (es) Uso de elsiglutida para tratar mucositis gastrointestinal que incluye diarrea inducida por quimioterapia.
UY37800A (es) AGENTES DE iARN PARA LA INHIBICIÓN DE LA EXPRESIÓN DE ALFA-ENaC Y MÉTODOS DE USO
CO2023015915A2 (es) Anticuerpos anti-ccr8
SV2019005811A (es) Combinación de un inhibidor de bcl-2 y un inhibidor de mcl1, usos y composiciones farmacéuticas de éstos
UY39393A (es) Formulaciones de un inhibidor de mcl-1
AR108616A1 (es) Formulación combinada de tres compuestos antivirales
MX2021005038A (es) Dispersiones solidas y composiciones farmaceuticas que comprenden un indano sustituido y metodos para la preparacion y uso de las mismas.
CL2018003013A1 (es) Uso de un inhibidor de la acetilcolinesterasa e idalopirdina para reducir las caídas en pacientes con la enfermedad de parkinson.